BioCentury | Jan 24, 2020
Preclinical News

Jan. 23 Preclinical Quick Takes: Metastasis-associated cancer-associated fibroblast populations; plus NIH-TeneoBio and Basilea

Cancer-associated fibroblast subsets linked to metastasis In a study published in Nature Communications , a team from Institut Curie and INSERM identified within breast cancer patients’ lymph nodes four subpopulations of cancer-associated fibroblasts (CAFs). Two subsets...
BioCentury | Oct 18, 2018
Distillery Therapeutics


INDICATION: Scars/wrinkles Patient sample and mouse studies suggest inhibiting CXCL12 could help treat scars. In injured skin samples from scar patients, CXCL12 levels were higher in patients aged 40 years or younger with thick scars...
BioCentury | Jul 27, 2018
Emerging Company Profile

Wound-up bacteria

Ilya Pharma AB has engineered bacteria to produce a protein that promotes wound closure as a more convenient and lower cost alternative to recombinant protein therapies that accelerate wound healing. According to CEO Evelina Vågesjö,...
BioCentury | May 24, 2018
Translation in Brief

Channel for T cell invasion

University of Cincinnati researchers have found that increasing potassium flux through the KCa3.1 channel could boost CD8 + T cell migration into the tumor microenvironment, raising the prospect that this could present a new mechanism...
BioCentury | Feb 13, 2018
Distillery Therapeutics


INDICATION: Wounds Patient sample and mouse studies suggest CXCL12-secreting Lactobacillus reuteri could help treat wounds. In a human skin biopsy-based model of wound healing, L. reuteri engineered to secrete CXCL12 increased the length of epidermal...
BioCentury | Feb 6, 2018
Preclinical News

Bacteria that secrete CXCL12 could enhance wound healing

In a study published in Proceedings of the National Academy of Sciences , the co-founders of Ilya Pharma AB (Uppsala, Sweden) showed topical delivery of Lactobacillus reuteri engineered to express chemokine CXC motif ligand 12 (CXCL12;...
BioCentury | Jul 14, 2017
Clinical News

Noxxon starts Phase I/II of olaptesed pegol, Keytruda combo in cancer

Noxxon Pharma N.V. (Euronext:ALNOX) began a 2-part Phase I/II trial to evaluate olaptesed pegol (NOX-A12) plus Keytruda pembrolizumab in about 10 patients with metastatic colorectal cancer and 10 patients with metastatic pancreatic cancer. Patients will...
BioCentury | Jul 7, 2017
Company News

Merck KGaA spins out cancer newco iOnctura with partner Cancer Research UK

Merck KGaA (Xetra:MRK) said that its Merck Ventures arm created immuno-oncology newco iOnctura S.A. (Geneva, Switzerland) with an undisclosed seed investment. The newco launched with two unnamed assets spun out of Merck’s Healthcare R&D portfolio,...
BioCentury | Jan 27, 2017
Emerging Company Profile

Cardiac conversion

Cell therapies that aim to reverse disease progression in heart failure and myocardial infarction by restoring cardiomyocytes are beginning to report positive clinical data, but they require frequent administration via invasive procedures. Tenaya Therapeutics Inc....
BioCentury | Nov 30, 2016
Distillery Therapeutics


INDICATION: Breast cancer; colorectal cancer Mouse studies suggest that liver expression of a CXCL12 trap protein could help treat liver metastases in colorectal cancer and breast cancer. In a mouse model of metastatic colorectal cancer,...
Items per page:
1 - 10 of 126